BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33997167)

  • 1. Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin resistance.
    Tung KL; Chen KY; Negrete M; Chen T; Safi A; Aljamal AA; Song L; Crawford GE; Ding S; Hsu DS; Shen X
    Genes Dis; 2021 Mar; 8(2):203-214. PubMed ID: 33997167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
    Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
    J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JUNB mediates oxaliplatin resistance via the MAPK signaling pathway in gastric cancer by chromatin accessibility and transcriptomic analysis.
    Li S; Wei Y; Sun X; Liu M; Zhu M; Yuan Y; Zhang J; Dong Y; Hu K; Ma S; Zhang X; Xu B; Jiang H; Gan L; Liu T
    Acta Biochim Biophys Sin (Shanghai); 2023 Nov; 55(11):1784-1796. PubMed ID: 37337631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution.
    Chen G; Gong T; Wang Z; Wang Z; Lin X; Chen S; Sun C; Zhao W; Kong Y; Ai H; Yang H; Liu Y; Wu F; Kang J; Zhao S; Xiao X; Sun J; He A; Li Z
    Cell Oncol (Dordr); 2022 Dec; 45(6):1155-1167. PubMed ID: 36136268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction".
    Papaccio F; García-Mico B; Gimeno-Valiente F; Cabeza-Segura M; Gambardella V; Gutiérrez-Bravo MF; Alfaro-Cervelló C; Martinez-Ciarpaglini C; Rentero-Garrido P; Zúñiga-Trejos S; Carbonell-Asins JA; Fleitas T; Roselló S; Huerta M; Sánchez Del Pino MM; Sabater L; Roda D; Tarazona N; Cervantes A; Castillo J
    J Exp Clin Cancer Res; 2023 Jan; 42(1):8. PubMed ID: 36604765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids.
    Li Q; Sun H; Luo D; Gan L; Mo S; Dai W; Liang L; Yang Y; Xu M; Li J; Zheng P; Li X; Li Y; Wang Z
    J Exp Clin Cancer Res; 2021 Nov; 40(1):348. PubMed ID: 34740372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity.
    Shi X; Li Y; Yuan Q; Tang S; Guo S; Zhang Y; He J; Zhang X; Han M; Liu Z; Zhu Y; Gao S; Wang H; Xu X; Zheng K; Jing W; Chen L; Wang Y; Jin G; Gao D
    Nat Commun; 2022 Apr; 13(1):2169. PubMed ID: 35449156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform.
    Forsythe SD; Sasikumar S; Moaven O; Sivakumar H; Shen P; Levine EA; Soker S; Skardal A; Votanopoulos KI
    Ann Surg Oncol; 2020 Dec; 27(13):4950-4960. PubMed ID: 32632882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromatin Remodeling in Patient-Derived Colorectal Cancer Models.
    Xiang K; Wang E; Mantyh J; Rupprecht G; Negrete M; Sanati G; Hsu C; Randon P; Dohlman A; Kretzschmar K; Bose S; Giroux N; Ding S; Wang L; Balcazar JP; Huang Q; Sundaramoorthy P; Xi R; McCall SJ; Wang Z; Jiang C; Kang Y; Kopetz S; Crawford GE; Lipkin SM; Wang XF; Clevers H; Hsu D; Shen X
    Adv Sci (Weinh); 2024 Apr; 11(16):e2303379. PubMed ID: 38380561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of SUV420H2-Dependent Chromatin Compaction Drives Right-Sided Colon Cancer Progression.
    Boonsanay V; Mosa MH; Looso M; Weichenhan D; Ceteci F; Pudelko L; Lechel A; Michel CS; Künne C; Farin HF; Plass C; Greten FR
    Gastroenterology; 2023 Feb; 164(2):214-227. PubMed ID: 36402192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tailored chemotherapy for colorectal cancer peritoneal metastases based on a drug-screening platform in patient-derived organoids: a case report.
    Prieto I; Barbáchano A; Rodríguez-Salas N; Viñal D; Cortés-Guiral D; Muñoz A; Fernández-Barral A
    J Gastrointest Oncol; 2023 Feb; 14(1):442-449. PubMed ID: 36915469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
    Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
    Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients.
    Geevimaan K; Guo JY; Shen CN; Jiang JK; Fann CSJ; Hwang MJ; Shui JW; Lin HT; Wang MJ; Shih HC; Li AF; Chang SC; Yang SH; Chen JY
    Front Oncol; 2022; 12():883437. PubMed ID: 35719949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance.
    Harada K; Sakamoto N; Ukai S; Yamamoto Y; Pham QT; Taniyama D; Honma R; Maruyama R; Takashima T; Ota H; Takemoto Y; Tanabe K; Ohdan H; Yasui W
    Gastric Cancer; 2021 Nov; 24(6):1264-1277. PubMed ID: 34272617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer.
    Boos SL; Loevenich LP; Vosberg S; Engleitner T; Öllinger R; Kumbrink J; Rokavec M; Michl M; Greif PA; Jung A; Hermeking H; Neumann J; Kirchner T; Rad R; Jung P
    Cell Mol Gastroenterol Hepatol; 2022; 13(2):517-540. PubMed ID: 34700030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Drug-Response Prediction Model of APC Mutant Colon Cancer Patient-Derived Organoids for Precision Medicine.
    Shin YJ; Jo EH; Oh Y; Kim DS; Hyun S; Yu A; Hong HK; Cho YB
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Proteome Profiles of Healthy and Tumor Human Colon Organoids Reveal Both Individual Diversity and Basic Features of Colorectal Cancer.
    Cristobal A; van den Toorn HWP; van de Wetering M; Clevers H; Heck AJR; Mohammed S
    Cell Rep; 2017 Jan; 18(1):263-274. PubMed ID: 28052255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response.
    Shen X; Zhang Y; Xu Z; Gao H; Feng W; Li W; Miao Y; Xu Z; Zong Y; Zhao J; Lu A
    Cell Death Dis; 2022 Apr; 13(4):303. PubMed ID: 35379798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture.
    Usui T; Sakurai M; Umata K; Elbadawy M; Ohama T; Yamawaki H; Hazama S; Takenouchi H; Nakajima M; Tsunedomi R; Suzuki N; Nagano H; Sato K; Kaneda M; Sasaki K
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29642386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic and epigenomic responses to aspirin in human colonic organoids.
    Witonsky D; Bielski MC; Li J; Lawrence KM; Mendoza IN; Usman H; Kupfer SS
    Physiol Genomics; 2023 Mar; 55(3):101-112. PubMed ID: 36645669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.